Related Experiment Video
Updated: May 23, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Formulation and hypoglycemic activity of pioglitazone-cyclodextrin inclusion complexes.
A A Elbary1, M A Kassem, M M Abou Samra
1Department of Pharmaceutical Technology, National Research Centre, Dokki, Cairo, Egypt.
Drug Discoveries & Therapeutics
|April 17, 2012
Summary
Pioglitazone
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery
- Physical Chemistry
Background:
- Pioglitazone, a thiazolidinedione, treats type 2 diabetes but suffers from poor solubility and dissolution.
- These limitations can reduce its therapeutic efficacy.
- Enhancing pioglitazone's solubility is crucial for improved bioavailability.
Purpose of the Study:
- To formulate a more soluble pioglitazone product at physiological pH.
- To investigate the interaction of pioglitazone with cyclodextrins and water-soluble polymers.
- To enhance pioglitazone's bioavailability and therapeutic efficacy.
Main Methods:
- Formation of 1:1 inclusion complexes of pioglitazone with various cyclodextrins (β-cyclodextrin, HP-β-cyclodextrin, dimethyl-β-cyclodextrin).
- Preparation of binary and ternary systems using the kneading method.
- Characterization of complexes using IR spectroscopy, X-ray diffractometry, and thermogravimetric analysis.
- Evaluation of dissolution rates, permeation through a cellulose membrane, and hypoglycemic effect in rats.
Main Results:
- Spectrophotometric and solubility studies confirmed the formation of 1:1 pioglitazone-cyclodextrin inclusion complexes.
- Ternary systems with water-soluble polymers (PVP, HPMC) showed significantly enhanced dissolution rates and efficiency compared to binary systems.
- Complexation increased pioglitazone's permeation and demonstrated a greater hypoglycemic effect, particularly the pioglitazone-DM β-cyclodextrin complex.
Conclusions:
- Complexation with cyclodextrins significantly improves the physicochemical and biological properties of pioglitazone.
- The addition of water-soluble polymers further enhances these improvements, leading to superior dissolution and bioavailability.
- This approach offers a promising strategy for developing more effective pioglitazone formulations for type 2 diabetes treatment.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...